Digi International Prevails in Patent Infringement Case

Federal Court Invalidates Patent Claims of Airgain Subsidiary

MINNEAPOLIS--(BUSINESS WIRE)-- Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, announced today that the U.S. District Court for the District of Minnesota has found all patent claims asserted by NimbeLink Corporation against Digi International to be invalid. NimbeLink is a subsidiary of Airgain Inc. (NASDAQ: AIRG).

In a lawsuit filed in September 2022, the Airgain subsidiary had alleged that certain Digi products infringed two patents related to NimbeLink’s Skywire® cellular modems (U.S. Patent Nos. 9,497,570 and 9,838,066). On March 14, 2024, the Court issued a ruling rendering all of NimbeLink’s asserted patent claims invalid.

The Court’s ruling invalidating NimbeLink’s patent claims follows another ruling last year in which the Court dismissed NimbeLink’s contract claims against Digi.

“We are pleased with the Court’s finding that these Airgain family patents are invalid,” said Ron Konezny, Digi’s President and Chief Executive Officer.

For more information about Digi International and its solutions, please visit www.digi.com.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507816952/en/

Peter Ramsay
Global Results Communications
[email protected]
949.307.5908

Source: Digi International

You May Also Be Interested In

• Vedanta Aluminium Reports Record Q1 FY27 Performance; Profit Surges 205%, EBITDA More Than Doubles
• Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
• Europe’s Largest Celebration of Irish Culture Arrives in Belfast